307 related articles for article (PubMed ID: 22996738)
1. Functional p53 determines docetaxel sensitivity in prostate cancer cells.
Liu C; Zhu Y; Lou W; Nadiminty N; Chen X; Zhou Q; Shi XB; deVere White RW; Gao AC
Prostate; 2013 Mar; 73(4):418-27. PubMed ID: 22996738
[TBL] [Abstract][Full Text] [Related]
2. Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.
Gan L; Wang J; Xu H; Yang X
Prostate; 2011 Aug; 71(11):1158-66. PubMed ID: 21656826
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
Ogura T; Tanaka Y; Tamaki H; Harada M
Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
[TBL] [Abstract][Full Text] [Related]
5. Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis.
Brown SG; Knowell AE; Hunt A; Patel D; Bhosle S; Chaudhary J
Prostate; 2015 Feb; 75(3):266-79. PubMed ID: 25327819
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone agonists sensitize, and resensitize, prostate cancer cells to docetaxel in a p53-dependent manner.
Moretti RM; Montagnani Marelli M; Taylor DM; Martini PG; Marzagalli M; Limonta P
PLoS One; 2014; 9(4):e93713. PubMed ID: 24722580
[TBL] [Abstract][Full Text] [Related]
7. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
[TBL] [Abstract][Full Text] [Related]
9. [Expression of AXL enhances docetaxel-resistance of prostate cancer cells].
Lin JZ; Zhu JG; Wu HF; Li JM; DE W; Wang ZJ
Zhonghua Nan Ke Xue; 2017 Apr; 23(4):302-308. PubMed ID: 29714413
[TBL] [Abstract][Full Text] [Related]
10. p53 interferes with microtubule-stabilizing agent-induced apoptosis in prostate and colorectal cancer cells.
Kim JY; Chung JY; Lee SG; Kim YJ; Park JE; Yun J; Park YC; Kim BG; Yoo YH; Kim JM
Int J Mol Med; 2013 Jun; 31(6):1388-94. PubMed ID: 23563592
[TBL] [Abstract][Full Text] [Related]
11. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
[TBL] [Abstract][Full Text] [Related]
12. NF-kappaB activation enhances cell death by antimitotic drugs in human prostate cancer cells.
Parrondo R; de las Pozas A; Reiner T; Rai P; Perez-Stable C
Mol Cancer; 2010 Jul; 9():182. PubMed ID: 20618955
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
Radhakrishnan S; Miranda E; Ekblad M; Holford A; Pizarro MT; Lemoine NR; Halldén G
Hum Gene Ther; 2010 Oct; 21(10):1311-25. PubMed ID: 20497039
[TBL] [Abstract][Full Text] [Related]
14. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells.
Yoo J; Park SS; Lee YJ
J Cell Biochem; 2008 Aug; 104(5):1636-46. PubMed ID: 18404675
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells.
Wang Q; He WY; Zeng YZ; Hossain A; Gou X
Int Urol Nephrol; 2018 Apr; 50(4):675-686. PubMed ID: 29460131
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel.
Uzoh CC; Holly JM; Biernacka KM; Persad RA; Bahl A; Gillatt D; Perks CM
Br J Cancer; 2011 May; 104(10):1587-93. PubMed ID: 21487405
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway.
Singh SK; Banerjee S; Acosta EP; Lillard JW; Singh R
Oncotarget; 2017 Mar; 8(10):17216-17228. PubMed ID: 28212547
[TBL] [Abstract][Full Text] [Related]
19. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
20. Developmentally regulated GTP-binding protein 2 levels in prostate cancer cell lines impact docetaxel-induced apoptosis.
Kim SC; Lee WH; Kim SH; Abdulkhayevich AA; Park JW; Kim YM; Moon KH; Lee SH; Park S
Investig Clin Urol; 2021 Jul; 62(4):485-495. PubMed ID: 34190439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
